Pacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study - PCRX News | RalliesPacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study
P
PCRX• PCRX-201 manufacturing transition and Phase 2 enrollment
- Pacira Biosciences shifted PCRX-201, a knee osteoarthritis gene therapy candidate, to a scalable U.S. commercial manufacturing process.
- The new supply enabled first patient enrollment in Part B of the Phase 2 ASCEND study.
- Topline results from Part A remain scheduled for end-2026, following completion of Part A enrollment in June.
- Manufacturing transition supports planned registrational development, with no delay to the ongoing Phase 2 program.
